• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Allen S. Melemed - Articles and news items

Lilly announces results from lung cancer study

Industry news, News / 6 September 2012 / Eli Lilly and Company

The Phase III POINTBREAK trial did not meet its primary endpoint…

Phase III study: patients with most common type of lung cancer lived longer with ALIMTA-based continuation maintenance therapy

Industry news, News / 4 June 2012 / Eli Lilly and Company

Overall survival data from PARAMOUNT study submitted to FDA…

Eli Lilly logo

Patients with deadly form of lung cancer lived longer without disease worsening

Industry news, News / 5 June 2011 / Eli Lilly and Company

Eli Lilly and Company announced that PARAMOUNT, met its primary endpoint of progression-free survival…